financetom
Business
financetom
/
Business
/
Travelers Third-Quarter Premiums Fall Short of Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travelers Third-Quarter Premiums Fall Short of Estimates
Oct 16, 2025 7:59 AM

10:19 AM EDT, 10/16/2025 (MT Newswires) -- Travelers (TRV) third-quarter written premiums fell short of market estimates, although the property and casualty insurer reported third-quarter earnings above expectations.

Net written premiums came in at $11.47 billion for the September quarter, ticking up from $11.32 billion a year earlier, but trailing the consensus on FactSet for $11.69 billion. The stock fell 3.5% in Thursday trade, but has gained 8% year-to-date.

In business insurance, net written premiums increased 3% to $5.68 billion led by a 7% rise in the company's core middle market segment, partially offset by national property and other. Personal insurance premiums nudged down to $4.72 billion from $4.73 billion, while bond and specialty inched 1% higher to $1.08 billion.

Adjusted earnings jumped to $8.14 from $5.24 year over year and surpassed the Street's view of $6.39. Core income benefitted from lower catastrophe losses, a higher underlying underwriting gain and an increase in net investment income, according to Travelers.

Total revenue advanced 5% to $12.47 billion, ahead of the average analyst estimate of $12.34 billion.

"We are very pleased to report another quarter of excellent results," Chief Executive Alan Schnitzer said in a statement. "Very strong underwriting results and higher investment income drove the bottom line."

Catastrophe losses, net of reinsurance, retreated to $402 million from $939 million in the 2024 quarter, the company said. Those losses were "fairly benign" and consisted mainly of tornado and hail events in the central US, Chief Financial Officer Dan Frey said during a conference call, according to a FactSet transcript.

The combined ratio, which indicates an underwriting profit if maintained under 100%, moved to 87.3% from 93.2% annually.

Price: 261.19, Change: -8.26, Percent Change: -3.07

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AlphaTON Capital, Subsidiary Tarus Therapeutics Explore Tokenization of Mesothelioma Drug TT-4 Economics
AlphaTON Capital, Subsidiary Tarus Therapeutics Explore Tokenization of Mesothelioma Drug TT-4 Economics
Oct 8, 2025
08:29 AM EDT, 10/08/2025 (MT Newswires) -- AlphaTON Capital ( ATON ) said Wednesday together with its oncology unit Tarus Therapeutics they have signed a non-binding letter of intent to explore tokenization of economics for mesothelioma program TT-4. AlphaTON, which also operates a strategic Toncoin (TON-USD) treasury, said the initiative could serve as a model for advancing therapeutic development through...
US Government Shutdown Reportedly Contributing to US Flight Delays
US Government Shutdown Reportedly Contributing to US Flight Delays
Oct 8, 2025
08:28 AM EDT, 10/08/2025 (MT Newswires) -- Air traffic control staffing shortages caused by the US government shutdown continue to contribute to flight delays at US airports, according to media reports and tracking data. More than 500 flights were delayed early Wednesday and 25 canceled, according to the aviation traffic tracking website FlightAware. Reuters identified airports in Houston, Nashville, Dallas,...
BRIEF-Transcode Announces The Acquisition Of Polynoma And A $25 Mln Financing By Subsidiary Of CK Life Sciences
BRIEF-Transcode Announces The Acquisition Of Polynoma And A $25 Mln Financing By Subsidiary Of CK Life Sciences
Oct 8, 2025
Oct 8 (Reuters) - Transcode Therapeutics Inc ( RNAZ ): * TRANSCODE THERAPEUTICS ( RNAZ ) ANNOUNCES THE ACQUISITION OF POLYNOMA AND A $25 MILLION STRATEGIC FINANCING BY A SUBSIDIARY OF CK LIFE SCIENCES TO FORM A FIRST-IN-CLASS UNIQUE IMMUNO-ONCOLOGY AND METASTATIC PREVENTION ONCOLOGY COMPANY * TRANSCODE THERAPEUTICS INC ( RNAZ ) - CONCURRENT EQUITY INVESTMENT OF $25 MILLION FROM...
OneOncology Expands in Florida by Acquiring GenesisCare, Will Relaunch as SunState Medical Specialists
OneOncology Expands in Florida by Acquiring GenesisCare, Will Relaunch as SunState Medical Specialists
Oct 8, 2025
Key Highlights 100+ physicians across urology, oncology, and surgical specialties caring for patients across Florida  Significant investments planned to upgrade technology and expand access to advanced clinical services Partnership strengthens OneOncology's position as the nation's leading physician-led platform for medical oncology, urology, and radiation oncology NASHVILLE, Tenn., Oct. 8, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform empowering independent medical specialty...
Copyright 2023-2026 - www.financetom.com All Rights Reserved